Accustem Sciences (ACUT) Change in Accured Expenses (2021 - 2025)
Accustem Sciences (ACUT) posted quarterly Change in Accured Expenses of -$147901.0 for Q4 2025, down 3540.19% quarter-over-quarter from -$4063.0 in Q3 2025.
Accustem Sciences (ACUT) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Accustem Sciences (ACUT) has reported Change in Accured Expenses for 5 consecutive years, with -$147901.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses changed N/A year-over-year to -$147901.0; the TTM figure through Dec 2025 stood at -$162180.0 (down 2228.35% YoY), while the FY2025 annual figure was -$162180.0, down 2228.35% from the prior year.
- Change in Accured Expenses fell to -$147901.0 in Q4 2025 per ACUT's latest filing, from -$4063.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $206010.0 in Q1 2023 and bottomed at -$352393.0 in Q2 2023.
- Historically, Change in Accured Expenses has averaged -$1452.0 across 5 years, with a median of $5936.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 12989.3% — and 2023, when it plunged 417.42%.
- Accustem Sciences' Change in Accured Expenses stood at $82295.0 in 2021, then surged by 108.02% to $171190.0 in 2022, then tumbled by 278.49% to -$305552.0 in 2023, then surged by 103.0% to $9155.0 in 2024, then sank by 1715.52% to -$147901.0 in 2025.
- Business Quant data shows ACUT's Change in Accured Expenses at -$147901.0 in Q4 2025, -$4063.0 in Q3 2025, and $5936.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -147,901.00 |
| Dec 31, 2025 | -147,901.00 |
| Sep 30, 2025 | -4,063.00 |
| Sep 30, 2025 | -4,063.00 |
| Jun 30, 2025 | 5,936.00 |
| Jun 30, 2025 | 5,936.00 |
| Mar 31, 2025 | -16,152.00 |
| Mar 31, 2025 | -16,152.00 |
| Sep 30, 2024 | 9,155.00 |
| Sep 30, 2024 | 9,155.00 |
| Jun 30, 2024 | -64,668.00 |
| Jun 30, 2024 | -64,668.00 |
| Mar 31, 2024 | 63,133.00 |
| Mar 31, 2024 | 63,133.00 |
| Dec 31, 2023 | -305,552.00 |
| Dec 31, 2023 | -305,552.00 |
| Sep 30, 2023 | 99,423.00 |
| Sep 30, 2023 | 99,423.00 |
| Jun 30, 2023 | -352,393.00 |
| Jun 30, 2023 | -352,393.00 |